Open an account

Creative Medical Technology Holdings

CELZ · NASDAQ

$0.7547−$0.0016 (−0.21%)TodayMarket closed ·
Prev close $0.7563

About CELZ

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. The company is headquartered in Phoenix, Arizona and currently employs 4 full-time employees. The company went IPO on 2009-05-01. The firm conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.

Employees
4
Headquarters
Phoenix, Arizona
Listed
May 1, 2009
Sector
Health Care
Industry
Biotechnology
Website
creativemedicaltechnology.com

CELZ key statistics

Market cap
4.98M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.21M
Volume
1
Open price
$0.727
High today
$0.78
Low today
$0.68
52 Week high
$6.25
52 Week low
$0.62

Creative Medical Technology Holdings (CELZ) at a glance

As of Oct 21, 2026, Creative Medical Technology Holdings (CELZ) shares are priced at $0.7547, giving the company a market cap of 4.98M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.68 and $0.78. The current price is 11.0% above the day's low and 3.2% below its high.

Volume so far is 1 shares, below the average of 1.21M shares a day.

Over the past year Creative Medical Technology Holdings has ranged from $0.62 to $6.25, and now sits 2% of the way up that range.

Creative Medical Technology Holdings met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.41 per share against an estimate of -$0.3978.

CELZ earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 11.3% on average.

  1. Q3 FY24: reported -$0.75 per share against an estimate of -$0.867
  2. Q4 FY24: reported -$1.12 per share against an estimate of -$0.6426
  3. Q1 FY25: reported -$0.83 per share against an estimate of -$0.5304
  4. Q2 FY25: reported -$0.48 per share against an estimate of -$0.6426
  5. Q3 FY25: reported -$0.48 per share against an estimate of -$0.4896
  6. Q4 FY25: reported -$0.73 per share against an estimate of -$0.3774
  7. Q1 FY26: reported -$0.38 per share against an estimate of -$0.3978
  8. Q2 FY26: reported -$0.41 per share against an estimate of -$0.3978

CELZ news

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Henry Khederian

    Creative Medical Technology Stock Surges After Key Patent Win

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releaseGlobe Newswire

    Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds

Similar companies

Companies in the same industry as Creative Medical Technology Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.